Plain-English translation of NCT05357781 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is looking at whether people with multiple sclerosis (MS) who have low levels of immunoglobulin G (IgG)—a type of antibody that helps fight infection—experience more fatigue than those with normal antibody levels. Researchers want to understand if low antibodies might be one reason why MS patients feel so tired, and whether treating this deficiency could help. The study will compare fatigue in two groups of MS patients: those with low antibody levels and those with normal levels.
Fatigue affects about 75% of people with MS and is a major reason patients miss work or leave their jobs, yet there are no proven treatments for it. Recent research suggests that some MS patients develop low antibody levels, which might contribute to fatigue—similar to what happens in other immune disorders. This study aims to fill that gap by investigating whether low antibodies could be an overlooked, treatable cause of MS-related tiredness.
You likely qualify if…
You likely don't qualify if…
This is an observational study, meaning researchers will track and compare your experiences rather than give you a new medication to test. You would complete questionnaires about your fatigue levels and other symptoms, and researchers would review your medical records and possibly do blood tests to measure your antibody levels. The study involves visits to the hospital over a period of time, during which you'll share information about how tired you feel and answer questions about your health—helping researchers understand the connection between low antibodies and fatigue in MS.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Switzerland
Sponsor
Insel Gruppe AG, University Hospital Bern
Enrollment target
~106 participants
Started
July 2022
Primary completion
December 2026
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lara Diem, MD
Inselspital University Hospital of Bern
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.